| Literature DB >> 35260182 |
Eimear C Morrissey1,2, Molly Byrne3, Bláthín Casey4, Dympna Casey5, Paddy Gillespie6,7, Anna Hobbins6,7, Michelle Lowry8, Elizabeth McCarthy3,8, John Newell9, Davood Roshan9, Shikha Sharma6, Sean F Dinneen8,10.
Abstract
BACKGROUND: The D1 Now intervention is designed to improve outcomes in young adults living with type 1 diabetes. It consists of three components: an agenda-setting tool, an interactive messaging system and a support worker. The aim of the D1 Now pilot cluster randomised controlled trial (RCT) was to gather and analyse acceptability and feasibility data to allow (1) further refinement of the D1 Now intervention, and (2) determination of the feasibility of evaluating the D1 Now intervention in a future definitive RCT.Entities:
Keywords: Behaviour change; Feasibility; Pilot randomised controlled trial; Type 1 diabetes; Young adults
Year: 2022 PMID: 35260182 PMCID: PMC8902268 DOI: 10.1186/s40814-022-00986-5
Source DB: PubMed Journal: Pilot Feasibility Stud ISSN: 2055-5784
Fig. 1The D1 Now agenda-setting tool
Fig. 2D1 Now intervention delivery timeline
Fig. 3The D1 Now pilot RCT design
Inclusion criteria
| Inclusion criteria for diabetes centres | Inclusion criteria for participants |
|---|---|
• A dedicated young adult clinic for people with type 1 diabetes • The young adult clinic should operate separately from other type 1 diabetes clinics that cater to young people, e.g. pump clinics and transition clinics • Eligible diabetes centres must have at least one full-time Diabetologist, Diabetes Specialist Nurse and Diabetes Specialist Dietician | • A confirmed diagnosis of type 1 diabetes for more than 12 months • Aged between 18 and 25 years on the date of recruitment • Participants on insulin pump therapy or using continuous glucose monitoring devices are eligible to participate • Participants must have access to a mobile phone. |
Fig. 4CONSORT flow diagram
Patient outcome measures taken at baseline and 12 months
| Construct to be measured | How was it measured? |
|---|---|
| Demographics | Self-report: gender, age, education status, occupation, duration of diabetes, co-morbidities, current insulin regimen, glucose monitoring method and other (non-insulin) medication. |
| Glycated haemoglobin (HbA1c) | Laboratory HbA1c within the last 3 months; if this was unavailable, the most recent point-of-care HbA1c result was used |
| Number of instances of diabetic ketoacidosis (DKA) | Medical record review and patient self-report; timeframe was over the past 12 months. |
| Number of instances of severe hypoglycaemia | Medical record review and patient self-report; timeframe was over the past 12 months. |
| Clinic engagement | This was operationalised as clinic attendance and was obtained from the clinic appointment administration system; timeframe was over the past 12 months. |
| Diabetes distress | Self-report: Measured using the Problems Areas in Diabetes-11 (PAID-11) scale [ |
| Diabetes related quality of life | Self-report: Measured using the Audit of Diabetes Dependent Quality of life (ADDQOL) [ |
| Diabetes related self-management | Self-report: Measured using the Diabetes Self-Management Questionnaire (DSMQ) [ |
| Perceived level of control of diabetes | Self-report: Measured using the Diabetes Empowerment Scale-Short Form (DES-SF; 10) [ |
Quantitative evaluation of acceptability and feasibility of the D1 Now intervention and pilot cluster RCT methods
| 1. Recruitment of diabetes centres was assessed by documenting the number of invitations sent, the number of refusals and number of acceptances. | |
| 2. Recruitment of participants was assessed by documenting the number of invitations sent, the number of initial responses, the number of follow-up phone calls required, the number of refusals and the number of acceptances. | |
| 3. Loss to follow-up of participants was documented at every time point. | |
| 4. Levels of missing data in completed questionnaires are reported. | |
| 5. The comprehensibility and acceptability of all questionnaires were measured by asking participants how the questionnaires might be improved and how long they took to complete. | |
| 6. Engagement with Florence is reported. | |
| 7. The level to which the agenda-setting tool is used, in particular any missing sections, was documented. |
Participant baseline demographics (young adult participants: n = 57; staff participants: n = 30)
| Intervention arm 1 | Intervention arm 2 | Control arm | |
|---|---|---|---|
| External support worker | Internal support worker | Treatment as usual | |
| 20.3 (1.8) | 20.7 (1.8) | 20.6 (1.9) | |
| Male | 7 | 9 | 3 |
| Female | 16 | 14 | 6 |
| Single | 22 | 23 | 9 |
| Cohabiting | 1 | – | – |
| 10.4 (4.9) | 9.4 (4.4) | 10.2 (4.7) | |
| Pen | 15 | 14 | 7 |
| Insulin pump | 8 | 9 | 2 |
| Finger prick | 5 | 9 | 2 |
| Continuous glucose monitor | 1 | 8 | 1 |
| Flash glucose monitor | 17 | 6 | 6 |
| Completed | 3 | 2 | 5 |
| Referred | 6 | 4 | 2 |
| Declined | 4 | 6 | 1 |
| Not offered | 10 | 8 | 1 |
| Administrator | 1 | 2 | 3 |
| Nurse | – | 3 | – |
| Diabetes Specialist Nurse | 1 | 1 | 3 |
| Dietician | 1 | 1 | 2 |
| Non-consultant Hospital Doctor | 3 | 2 | 3 |
| Consultant Endocrinologist | 1 | 2 | 1 |
Outcome measures at baseline and follow-up
| Baseline | Twelve months | |||||
|---|---|---|---|---|---|---|
| Intervention Arm 1 | Intervention Arm 2 | Control Arm | Intervention Arm 1 | Intervention Arm 2 | Control Arm | |
| External support Worker ( | Internal support Worker ( | Treatment as usual ( | External support Worker ( | Internal support Worker ( | Treatment as usual ( | |
| PAID-11, mean (SD) | 19.2(8.8) | 19.5(8.0) | 20.9(7.6) | 17.4 (8.2) | 16.1 (8.1) | 16.8 (11.0) |
| DSMQ, mean (SD) | 2.39 (0.8) | 5.3 (1.2) | 5.1(1.) | 4.7 (1.3) | 5.1 (1.7) | 5.4 (0.87) |
| DES-SF, mean (SD) | 3.5 (0.8) | 3.8 (0.9) | 3.7 (0.5) | 3.9 (0.7) | 3.6 (1.1) | 3.7 (0.5) |
| ADDQOL, mean (SD) | − 3.3 (1.2) | − 3.8 (1.8) | − 4.1 (1.7) | − 4.7 (2.0) | − 3.4 (1.6) | − 3.3 (0.6) |
| HbA1c, mean (SD) | 80.2 (17.9) | 67.6 (20.2) | 64.5 (12.3) | 70.2 (16.0) | 65.1 (12.1) | 58.7 (16.1) |
| Clinic appointments attended: past 12 months, mean (SD) | 2.1 (0.8) | 2.6 (0.9) | 1.8 (0.7) | 3.4 (1.0) | 2.6 (0.6) | 1.6 (0.7) |
| Number of episodes of DKA in past 12 months | 0: | 0: | 0: | 0: | 0: n = 16 | 0: |
| 1: | 1: | 1: | 1: | 1: | 1: | |
| > 1: | > 1: | > 1: | > 1: | > 1: | > 1: | |
| Number of episodes of severe hypoglycaemia in past 12 months | 0: | 0: | 0: | 0: | 0: | 0: |
| 1: | 1: | 1: | 1: | 1: | 1: | |
| > 1: | > 1: | > 1: | > 1: | > 1: | > 1: | |
SD standard deviation
Resource use and EQ-5D-5L estimates at baseline and follow-up
| Variable/time point | Baseline | Follow-up: 12 months | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervention arm 1 | Intervention arm 2 | Control arm | Intervention arm 1 | Intervention arm 2 | Control arm | |||||||
| External support worker | Internal support worker | Treatment as usual | External support worker | Internal support worker | Treatment as usual | |||||||
| GP visits | 2.5 | (2.5) | 2.4 | (1.9) | 4.1 | (3.9) | 1.00 | (1.6) | 1.2 | (1.2) | 1.9 | (1.7) |
| Practice Nurse visits | 0.0 | (0.0) | 0.4 | (1.0) | 0.1 | (0.3) | 0.3 | (1.1) | 0.7 | (1.4) | 0.0 | (0.0) |
| Psychologist visit | 1.5 | (4.1) | 0.8 | (1.8) | 0.0 | (0.0) | 1.7 | (6.4) | 2.5 | (6.6) | 6.5 | (15.9) |
| Diabetes Specialist Nurse visit | 2.2 | (1.7) | 2.2 | (1.9) | 2.2 | (2.4) | 0.7 | (1.4) | 1.7 | (1.4) | 0.7 | (0.8) |
| Dietician visit | 1.3 | (2.7) | 0.9 | (1.3) | 1.4 | (1.1) | 0.3 | (0.6) | 0.2 | (0.6) | 0.7 | (0.8) |
| Diabetes Day Centre | 1.9 | (1.4) | 2.3 | (1.3) | 1.6 | (0.8) | 2.2 | (1.6) | 1.2 | (1.0) | 0.8 | (1.0) |
| Outpatient visits | 0.8 | (3.0) | 0.3 | (0.6) | 0.9 | (1.5) | 0.5 | (1.6) | 0.4 | (0.7) | 0.8 | (1.5) |
| Inpatient days | 0.1 | (0.5) | 0.6 | (1.6) | 0.1 | (0.3) | 0.0 | (0.0) | 0.1 | (0.2) | 0.0 | (0.0) |
| A&E visits | 0.4 | (0.7) | 0.4 | (0.7) | 1.3 | (1.4) | 0.1 | (0.3) | 0.4 | (0.6) | 0.5 | (0.5) |
| SA insulin* | 15 | (65%) | 18 | (78%) | 6 | (67%) | 11 | (48%) | 16 | (70%) | 6 | (67%) |
| LA insulin* | 12 | (52%) | 11 | (48%) | 6 | (67%) | 6 | (26%) | 7 | (30%) | 4 | (44%) |
| Ultra-LA insulin* | 0 | (0%) | 0 | (0%) | 1 | (11%) | 0 | (0%) | 0 | (0%) | 1 | (11%) |
| Insulin pump* | 8 | (35%) | 10 | (43%) | 2 | (22%) | 6 | (26%) | 8 | (35%) | 2 | (22%) |
| Multiple daily injections* | 13 | (57%) | 12 | (52%) | 7 | (78%) | 8 | (35%) | 8 | (35%) | 4 | (44%) |
GP general practitioner, A&E accident and emergency, SA short acting, LA long acting
Completeness of data:
External support worker: Baseline—0% missing data for GP visits, 4% for practice nurse visits, 4% for Psychologist visit, 4% for Diabetes Specialist Nurse visits, 0% for Dietician Visit, 4% for Diabetes Day Centre visits, 22% for outpatient visits, 4% for hospital inpatient nights, 0% for A&E visits, 9% for insulin therapy, 9% insulin device used and 0% for EQ-5D-5L
External support worker: Follow-up—39% missing data on GP visits, Practice Nurse visits, Psychologist visit, Diabetes Specialist Nurse visits, Dietician Visit, Diabetes Day Centre visits, outpatient visits, hospital inpatient nights, A&E visits insulin therapy, insulin device used, EQ-5D-5L and QALYs
Internal support worker: Baseline—4% missing data on GP visits, 9% Practice Nurse visits, 9% for Psychologist visit, 9% for Diabetes Specialist Nurse visits, 13% for Dietician Visit, 9% for Diabetes Day Centre visits, 30% for outpatient visits, 9% for hospital inpatient nights, 9% for A&E visits, 4% for insulin therapy, 4% insulin device used, and 0% for EQ-5D-5L
Internal support worker: Follow-up—26% missing data on GP visits, Practice Nurse visits, Psychologist visit, Diabetes Specialist Nurse visits, Dietician Visit, Diabetes Day Centre visits, hospital inpatient nights, A&E visits, insulin therapy, insulin device used, EQ-5D-5L and QALYs. 30% missing data for outpatient visits
Treatment as usual: Baseline—0% missing data for GP visits, Practice Nurse visits, Psychologist visit, Diabetes Specialist Nurse visits, Dietician Visit, Diabetes Day Centre visits, outpatient visits, A&E visits, hospital inpatient nights, insulin therapy, insulin device used and EQ-5D-5L
Treatment as usual: Follow-up—33% missing data on GP visits, Practice Nurse visits, Psychologist visit, Diabetes Specialist Nurse visits, Dietician Visit, Diabetes Day Centre visits, hospital inpatient nights, A&E visits, for insulin therapy, insulin device used, EQ-5D-5L and QALYs 56% missing data for outpatient visits
*Annualised costs were estimated and applied for insulin, pump and multiple daily injections
Costs, EQ5D scores and QALY estimates at baseline and follow-up
| Variable/time point | Baseline | Follow-up: 12 months | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervention arm 1 | Intervention arm 2 | Control arm | Intervention arm 1 | Intervention arm 2 | Control arm | |||||||
| External support worker | Internal support worker | Treatment as usual | External support worker | Internal support worker | Treatment as usual | |||||||
| GP visits | 125.00 | (122.98) | 119.05 | (94.51) | 205.56 | (194.37) | 50.00 | (77.83) | 60.00 | (62.22) | 95.83 | (84.29) |
| Practice Nurse visits | 0.00 | (0.00) | 14.64 | (41.58) | 4.56 | (13.67) | 11.71 | (43.83) | 28.94 | (57.55) | 0.00 | (0.00) |
| Psychologist visit | 148.50 | (407.33) | 77.79 | (177.49) | 0.00 | (0.00) | 169.71 | (635.01) | 247.5 | (648.24) | 643.50 | (1576.25) |
| Diabetes Specialist Nurse visit | 28.66 | (22.21) | 28.43 | (24.57) | 28.43 | (31.46) | 9.08 | (18.07) | 21.61 | (18.37) | 8.75 | (10.71) |
| Dietician visit | 81.71 | (172.42) | 58.50 | (82.08) | 90.28 | (68.52) | 20.00 | (40.98) | 15.29 | (36.55) | 43.33 | (53.07) |
| Diabetes Day Centre | 259.12 | (192.89) | 318.53 | (175.65) | 219.11 | (106.32) | 294.67 | (215.69) | 165.75 | (128.95) | 113.33 | (133.71) |
| Outpatient visits | 110.5 | (407.15) | 34.00 | (78.52) | 120.89 | (208.98) | 68.00 | (218.32) | 51.00 | (97.76) | 102.00 | (204.00) |
| Inpatient days | 133.29 | (446.06) | 540.16 | (1469.15) | 103.67 | (311.00) | 0.00 | (0.00) | 54.88 | (226.29) | 0.00 | (0.00) |
| A&E visits | 109.64 | (178.52) | 95.71 | (175.45) | 357.33 | (379.01) | 19.14 | (71.63) | 110.35 | (165.72) | 134.00 | (146.79) |
| SA insulin | 347.03 | (196.59) | 297.08 | (148.92) | 301.90 | (174.53) | 271.23 | (194.44) | 343.25 | (184.88) | 313.08 | (198.59) |
| LA insulin | 341.42 | (137.91) | 407.16 | (180.22) | 320.61 | (69.76) | 337.74 | (167.94) | 420.61 | (170.97) | 392.81 | (125.39) |
| Ultra-LA insulin | 0.00 | (0.00) | 0.00 | (0.00) | 396.48 | (0.00) | 0.00 | (0.00) | 0.00 | (0.00) | 352.43 | (0.00) |
| 3439 | (0.00) | 3439 | (0.00) | 3439 | (0.00) | 3439 | (0.00) | 3439 | (0.00) | 3439 | (0.00) | |
| 612 | (0.00) | 612 | (0.00) | 612 | (0.00) | 612 | (0.00) | 612 | (0.00) | 612 | (0.00) | |
| 2550.56 | (1358.01) | 3006.50 | (1844.00) | 2680.69 | (1674.14) | 2139.59 | (1488.82) | 2474.12 | (1761.75) | 2216.51 | (2705.10) | |
| 1803.57 | (0.00) | 1281.41 | (0.00) | €0.00 | (0.00) | |||||||
| EQ-5D-5L Score | 0.8 | (0.2) | 0.9 | (0.1) | 0.8 | (0.2) | 0.9 | (0.2) | 0.8 | (0.2) | 0.8 | (0.2) |
| QALY gained | 0.9 | (0.2) | 0.9 | (0.1) | 0.8 | (0.2) | ||||||
Completeness of data:
External support worker: Baseline—0% missing data for GP visits, 4% for Practice Nurse visits, 4% for Psychologist visit, 4% for Diabetes Specialist Nurse visits, 0% for Dietician Visit, 4% for Diabetes Day Centre visits, 22% for outpatient visits, 4% for hospital inpatient nights, 0% for A&E visits, 9% for insulin therapy, 9% insulin device used and 0% for EQ-5D-5L
External support worker: Follow-up—39% missing data on GP visits, Practice Nurse visits, Psychologist visit, Diabetes Specialist Nurse visits, Dietician Visit, Diabetes Day Centre visits, outpatient visits, hospital inpatient nights, A&E visits insulin therapy, insulin device used, EQ-5D-5L and QALYs
Internal support worker: Baseline—4% missing data on GP visits, 9% Practice Nurse visits, 9% for Psychologist visit, 9% for Diabetes Specialist Nurse visits, 13% for Dietician Visit, 9% for Diabetes Day Centre visits, 30% for outpatient visits, 9% for hospital inpatient nights, 9% for A&E visits, 4% for insulin therapy, 4% insulin device used, and 0% for EQ-5D-5L
Internal support worker: Follow-up—26% missing data on GP visits, Practice Nurse visits, Psychologist visit, Diabetes Specialist Nurse visits, Dietician Visit, Diabetes Day Centre visits, hospital inpatient nights, A&E visits, insulin therapy, insulin device used, EQ-5D-5L and QALYs. 30% missing data for outpatient visits
Treatment as usual: Baseline—0% missing data for GP visits, Practice Nurse visits, Psychologist visit, Diabetes Specialist Nurse visits, Dietician Visit, Diabetes Day Centre visits, outpatient visits, A&E visits, hospital inpatient nights, insulin therapy, insulin device used and EQ-5D-5L.
Treatment as usual: Follow-up—33 % missing data on GP visits, Practice Nurse visits, Psychologist visit, Diabetes Specialist Nurse visits, Dietician Visit, Diabetes Day Centre visits, hospital inpatient nights, A&E visits, for insulin therapy, insulin device used, EQ-5D-5L and QALYs. 56% missing data for outpatient visits
Summary of findings for the Decision-making after Pilot and feasibility Trials (ADePT) process [28]
| Methodological issue | Obja | Findings |
|---|---|---|
| 1. Did the study allow a sample size calculation for the definitive trial? | 4 | Using HbA1c as a primary outcome, the sample size for future randomised controlled trial was estimated to be 492 participants (41 participants from 12 clusters). |
| 2. What factors influenced eligibility and what proportion of those approached were eligible? | 1 | All diabetes centres approached were eligible. In order for young adult participants to be eligible, they had to meet the inclusion criteria and also have attended a clinic appointment between Oct 2019 and Jan 2020. |
| 3. Was recruitment successful? | 1 | Recruitment proceeded smoothly in 2 of the 4 centres. Due to differing ethics requirements, there were more barriers to recruitment which led to lower numbers of participants being recruited in the remaining 2 centres. |
| 4. Did eligible participants consent? | 1 | Consent was obtained successfully in all centres |
| 5. Were participants successfully randomised and did randomisation yield equality in groups? | 1 | This was a cluster randomised RCT. Randomisation was successful. However, one centre from the control arm left the study due to delays with ethics and the onset of COVID-19. This, along with additional ethics committee requirements around recruitment, meant the numbers of participants in the control arm was small (see CONSORT flow diagram for detail). |
| 6. Were blinding procedures adequate? | 1 | Not applicable to current study |
| 7. Did participants adhere to the intervention? | 1 | Young adult participants and support workers filled in the “study delivery checklist” after each appointment. Adherence was generally good. Three consistent deviations were identified: see text for details |
| 8. Was the intervention acceptable to participants? | 1 | Young adult participants’ perceptions of the agenda-setting tool and support worker were very positive. Their views on Florence were mixed. Staff held similar views on the intervention components but had an additional concern around resourcing of the Support Worker. |
| 9. Was it possible to calculate intervention costs and duration? | 3 | The implementation cost of the D1 Now intervention over 12 months was estimated at €1281 per young adult for the internal support worker arm and €1804 for the external support worker arm. |
| 10. Were outcome assessments completed? | 2 | Young adult self-reported outcomes were 100% completed at baseline and 71% at time 2. This second lower rate of completion was likely caused by time 2 data collection happening through the post, rather than in the clinic, due to COVID-19 related restrictions. Young adult clinical outcomes were 100% completed at baseline and time 2, with the exception of HbA1c, which again was impacted by COVID-19 related restrictions. |
| 11. Were outcomes measured the most appropriate outcomes? | 2 | Yes, outcomes were based on a core outcome set developed for this population [ |
| 12. Was retention to the study good? | 1 | Yes, there was just 12% attrition from baseline to follow-up. Details are in the CONSORT flow diagram. |
| 13. Were the logistics of running a multicentre trial assessed? | 1 | Yes. Patient recruitment and intervention delivery in a future definitive trial was identified as being resource intensive. The varying requirements of multiple different Research Ethics Committees were also identified as a challenge. |
| 14. Did all components of the protocol work together? | 1 | Yes, but some modifications are required to move forward to a definitive RCT. |
aStudy objective